Ente Ecclesiastico Ospedale Generale Regionale Miulli
- Address
- lock Available on a paid plan
Ente Ecclesiastico Ospedale Generale Regionale Miulli - Advanced Clinical Research Center
The Ente Ecclesiastico Ospedale Generale Regionale Miulli stands as a distinguished medical research institution conducting cutting-edge clinical trials across multiple therapeutic areas. The center demonstrates particular expertise in cardiovascular disease prevention, oncology therapeutics, and rare disease management, participating in both early-phase and advanced clinical investigations that address critical unmet medical needs.
- Cardiovascular disease research including lipid disorders and diabetes-related cardiovascular complications
- Gynecologic and urologic oncology trials focusing on ovarian cancer and bladder cancer with novel therapeutic approaches
- Rare disease studies in hereditary angioedema and IgA nephropathy with targeted treatment strategies
- Precision medicine initiatives incorporating biomarker-driven therapies and genetic profiling
The center's comprehensive research portfolio reflects its commitment to advancing personalized medicine approaches, from evaluating PARP inhibitors in BRCA-associated cancers to investigating RNA interference therapeutics for elevated lipoprotein(a). With active participation in international multicenter trials examining combination immunotherapy regimens, maintenance therapy strategies, and preventive interventions in high-risk populations, the institution contributes significantly to the development of next-generation treatments across diverse disease states.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 7 therapeutic areas and 15 of 36 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 14 by active trials.
lock +13 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Ente Ecclesiastico Ospedale Generale Regionale Miulli
lock Showing 1 of 21 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b Randomized Study of IMVT-1402 Versus Placebo in Adult Patients with Graves' Disease | Immunovant Sciences GmbH | Phase II | Recruiting | Nov 2025 | — |
IMP list
lock Showing 1 of 36 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cisplatin | 2 | Unknown | 2023-09-01 | 2025-01-09 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.